STOCK TITAN

Painreform Ltd - PRFX STOCK NEWS

Welcome to our dedicated page for Painreform news (Ticker: PRFX), a resource for investors and traders seeking the latest updates and insights on Painreform stock.

Company Overview

PainReform Ltd is a clinical-stage specialty pharmaceutical company dedicated to the reformulation of established pain therapeutics. With a focus on innovation within the postoperative analgesia and extended-release drug-delivery space, the company is committed to transforming pain management for both physicians and patients. By leveraging the FDA 505(b)(2) regulatory pathway, PainReform aims to enhance the clinical efficacy of existing medications while reducing adverse effects and optimizing dosing convenience.

Core Technologies and Therapeutic Advances

PainReform’s portfolio is anchored by its lead product candidate, PRF-110, which is based on the local anesthetic ropivacaine. Utilizing a proprietary, oil-based, viscous solution, PRF-110 is deposited directly into the surgical wound bed prior to closure. This innovative approach ensures localized, extended postoperative analgesia by maintaining therapeutic drug concentrations at the site of tissue injury over an extended period. The formulation addresses common limitations of traditional pain management therapies by reducing the necessity for repeated dosing and potentially lowering reliance on opioids.

Operational Strategy and Market Position

The company operates within the niche of drug reformulation, addressing specific clinical needs within the pain management segment. Through its disciplined focus on reformulating proven therapeutics, PainReform differentiates itself by applying unique technologies that enhance drug performance and patient compliance. The company’s operational model blends ongoing clinical research with strategic process improvements designed to bolster future commercialization efforts, thereby ensuring a resilient market presence in a dynamic therapeutic landscape.

Competitive Landscape and Differentiating Factors

PainReform competes in a complex landscape where innovation in drug delivery systems is critical to success. Unlike companies that develop entirely new molecular entities, PainReform capitalizes on reformulating established therapies to improve their safety and efficacy profiles. This approach allows the company to navigate regulatory pathways more efficiently while providing significant clinical benefits. Its extended-release technology is a key differentiator, offering both a therapeutic and operational advantage in a competitive market characterized by high standards of care and rigorous regulatory oversight.

Product Focus and Clinical Advantages

At the heart of PainReform’s clinical efforts is PRF-110, a product designed to address the unmet need for sustained postoperative pain relief. The product's oil-based, clear solution enables a streamlined mode of application and controlled drug release, tailoring pain management to the procedural landscape. By depositing the medication directly into the surgical wound bed, the company’s strategy minimizes the potential for systemic side effects and improves the overall patient experience. This method supports a growing clinical consensus that targeted, extended-release formulations can substantially improve postoperative recovery trajectories.

Industry Insights and Technological Integration

Within the specialty pharmaceutical sector, the intersection of drug reformulation and advanced delivery platforms represents a significant area of innovation. PainReform’s approach reflects a broader industry trend that prioritizes patient-centric therapies designed to deliver tangible clinical improvements. The integration of advanced drug-delivery systems not only refines the pharmacokinetic profile of established agents but also reinforces the company’s commitment to clinical excellence and operational efficiency. By adhering to rigorous regulatory standards and leveraging industry expertise, PainReform continues to evolve its technology platform, setting benchmarks in extended-release formulations and targeted therapeutic interventions.

Commitment to Quality and Clinical Validation

PainReform’s development strategy is reinforced by a commitment to clinical validation and quality assurance. Robust compatibility studies and ongoing clinical trials underscore the safety and efficacy of its formulations, positioning the company as a trusted entity within the pharmaceutical research community. Each phase of development is guided by stringent quality controls and backed by scientific data, ensuring that the therapeutic benefits of its products are communicated clearly to healthcare professionals and regulatory bodies alike.

Summary

In summary, PainReform Ltd stands as a specialist in the reformulation of pain therapeutics, harnessing innovative extended-release drug-delivery systems to address postoperative pain. Its focused approach, centered around PRF-110 and similar candidates, positions the company favorably within a competitive and evolving market. With an emphasis on clinical benefits, operational efficiency, and regulatory compliance, PainReform continues to advance a portfolio that is both strategic and clinically transformative, ensuring that it meets the essential needs of modern pain management.

Rhea-AI Summary

PainReform (Nasdaq: PRFX) has successfully developed and manufactured new patented formulations of its extended postoperative pain relief therapy, PRF-110. These formulations combine ropivacaine, a local anesthetic, with dexamethasone, an anti-inflammatory agent, to enhance postoperative recovery and pain management.

The company has created specific combination products containing 3.6% or 3.0% ropivacaine and 0.1-0.5% dexamethasone, which have shown promising stability in ongoing studies. This unique formulation addresses the challenge of product stability in ropivacaine-steroid mixtures.

PainReform's approach aims to provide superior pain management by combining the analgesic effects of ropivacaine with the anti-inflammatory properties of dexamethasone, potentially reducing reliance on opioids post-operatively.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
none
-
Rhea-AI Summary

PainReform (Nasdaq: PRFX) has announced favorable safety data for its lead product candidate, PRF-110, a post-operative pain management solution. Pharmacokinetic studies in herniorrhaphy and bunionectomy trials revealed maximum blood levels (Cmax) at approximately 10% of the FDA-established safety threshold for local anesthetics. This safety profile suggests PRF-110's potential for use in a broader range of surgical applications, possibly at higher doses.

PRF-110 is a viscous, oil-based solution applied directly to surgical wound beds, providing localized and extended postoperative analgesia. It uses ropivacaine, considered the safest long-acting local anesthetic, which may allow for higher doses and larger volumes compared to other anesthetics. This development could significantly reduce reliance on opioids and improve patient outcomes across various surgical procedures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.94%
Tags
none
-
Rhea-AI Summary

PainReform (Nasdaq: PRFX) has announced favorable wound healing data from human clinical trials for its lead product, PRF-110. The trials, involving both hard tissue (bunionectomy) and soft tissue (hernia) surgeries, showed that PRF-110 promoted normal wound healing and prevented scar formation. These results build upon previous preclinical studies that demonstrated PRF-110's compatibility with normal wound healing.

Key points:

  • PRF-110 contains 55% lecithin, which forms liposome-like structures potentially enhancing wound healing
  • No abnormalities in wound healing or scar formation were observed in patients treated with PRF-110
  • The company is on track to report top-line results from the Phase 3 trial in the second half of 2024

These findings support PRF-110's potential to provide effective post-surgical pain relief while promoting normal wound healing, potentially enhancing patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.83%
Tags
Rhea-AI Summary

PainReform (Nasdaq: PRFX) has announced a significant advancement in the development of its lead asset, PRF-110. The company's new highly scalable manufacturing process has enabled PRF-110 to achieve full product stability for 18 months at room temperature. This milestone is important for ensuring the drug's safety and efficacy, while also simplifying handling, transportation, and reducing associated costs.

The stability study is ongoing and marks a significant achievement for PainReform. The company recently filed a new patent for this manufacturing process, which is expected to significantly bolster future commercialization efforts. PainReform is on track to report top-line results from its Phase 3 trial in the second half of 2024, which will further inform the regulatory submission process and potential commercialization plans.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
none
-
Rhea-AI Summary

PainReform (Nasdaq: PRFX) has filed a patent for a new, highly scalable manufacturing process for PRF-110, its flagship post-operative pain control product. This development follows successful completion and testing of the process, marking a significant step towards potential market launch. The improved process includes:

  • Continuous Process Manufacturing for increased productivity
  • Single Reactor Manufacturing for reduced costs and contamination risk
  • Enhanced Batch Size capabilities while maintaining quality

These improvements are expected to reduce production costs and COGS for PRF-110. The company has completed its bunionectomy Phase 3 trial and believes PRF-110 could set a new standard in non-opioid post-operative pain relief.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.32%
Tags
none
-
Rhea-AI Summary

PainReform has successfully completed patient enrollment for the second part of its Phase 3 clinical trial for PRF-110, a novel analgesic drug candidate aimed at treating post-operative pain. The double-blind, placebo-controlled study enrolled 428 patients across eight U.S. sites. The trial's primary endpoint is to determine the drug's efficacy in reducing post-operative pain intensity over 72 hours compared to a placebo. Secondary endpoints include comparisons with Naropin and assessments of safety and rescue analgesic use. The company anticipates reporting top-line data in the second half of 2024, a critical step towards regulatory submission and potential commercialization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.61%
Tags
Rhea-AI Summary

PainReform, a clinical-stage specialty pharmaceutical company, announced it received a notification from Nasdaq indicating non-compliance with the minimum bid price requirement of $1.00 per share set forth in Listing Rule 5550(a)(2). The company has 180 days, from May 28, 2024, to November 25, 2024, to regain compliance by maintaining a closing bid price of at least $1 for a minimum of ten consecutive business days. Failure to do so may result in delisting, although the company may be eligible for an additional compliance period if it meets other listing standards. The notification does not immediately affect PainReform’s Nasdaq listing or trading under the symbol 'PRFX'.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
none
-
Rhea-AI Summary

PainReform provided a business update for Q1 2024, noting significant progress in the clinical development of its lead drug candidate, PRF-110.

The company reached 50% enrollment in the second part of its Phase 3 clinical trial for PRF-110 in bunionectomy, with over 200 patients enrolled across eight U.S. sites. No serious adverse events have been reported.

PainReform expects to announce top-line data in Q3 2024. New studies showed PRF-110's superior in-vitro release rates compared to industry leaders, and the company is optimistic about its potential to reduce opioid use.

Financially, R&D expenses rose to $4.7 million, mainly due to the Phase 3 trial, while general and administrative expenses decreased to $823,000. The company incurred a net loss of $5.5 million. As of March 31, 2024, PainReform held $4.3 million in cash and raised $4 million through a public offering in April 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

PainReform CEO, Ilan Hadar, discussed the benefits of PRF-110 in addressing the opioid epidemic during an interview with Proactiveinvestors.com. PRF-110 offers extended post-operative pain relief without opioids, with positive updates on the Phase 3 trial and market potential.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.43%
Tags
none
Rhea-AI Summary
PainReform, a clinical-stage specialty pharmaceutical company, announced the closing of a $4 million public offering, issuing 5,000,000 ordinary shares and warrants. The offering price was $0.80 per share with warrants exercisable immediately at the same price, expiring in five years. H.C. Wainwright & Co. acted as the exclusive placement agent. The net proceeds will be used for advancing clinical studies and general corporate purposes. The company also amended existing warrants to reduce the exercise price to $0.80 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags

FAQ

What is the current stock price of Painreform (PRFX)?

The current stock price of Painreform (PRFX) is $2.09 as of April 4, 2025.

What is the market cap of Painreform (PRFX)?

The market cap of Painreform (PRFX) is approximately 1.8M.

What is the primary focus of PainReform Ltd?

PainReform Ltd is focused on reformulating established pain therapeutics to improve efficacy, safety, and patient convenience. Its lead candidate, PRF-110, exemplifies its commitment to enhanced postoperative pain management.

How does PainReform differentiate its product offerings?

The company differentiates its product portfolio by utilizing a proprietary extended-release drug-delivery system that allows for prolonged localized analgesia. This reduces the need for repeated dosing and potentially lowers opioid requirements.

What regulatory pathway does PainReform utilize for its products?

PainReform leverages the US FDA 505(b)(2) regulatory pathway, which supports the reformulation of established therapeutics by relying on existing data to expedite development.

How does PRF-110 work in managing postoperative pain?

PRF-110 is a viscous, oil-based formulation based on ropivacaine. It is applied directly to the surgical wound bed, providing localized and sustained analgesic effects, thereby enhancing pain relief during the postoperative period.

What are the clinical advantages of PainReform's extended-release formulations?

The extended-release formulations offer sustained therapeutic drug levels at the site of administration, reducing the need for frequent dosing and lowering the risk of systemic side effects. This approach promotes better overall pain management and recovery.

How does PainReform maintain its competitive edge in the specialty pharmaceutical market?

By focusing on reformulation rather than entirely new molecular entities, PainReform benefits from established safety profiles while enhancing clinical performance. Its unique drug delivery innovations and adherence to rigorous regulatory standards further reinforce its competitive position.

What market segment does PainReform primarily serve?

PainReform primarily serves the postoperative pain management segment, addressing a significant need in surgical recovery through its localized and extended-release pain relief solutions.

How does PainReform ensure the quality and efficacy of its products?

Quality and efficacy are ensured through robust clinical research, stringent compatibility studies, and adherence to high regulatory standards. The company’s development process is characterized by ongoing clinical validation and scientific rigor.
Painreform Ltd

Nasdaq:PRFX

PRFX Rankings

PRFX Stock Data

1.85M
1.68M
0.79%
4.58%
7.21%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Israel
Tel Aviv